iRhythm (IRTC) Q2 2025 Earnings Call July 31, 2025 04:30 PM ET Speaker0Good afternoon. Thank you for attending today's iRhythm Technologies Inc. Q2 twenty twenty five Earnings Conference Call. My name is Bethany, and I will be the moderator for today's call. I would now like to pass the conference over to our host, Stephanie Dzabczyk, Senior Director of Investor Relations.Please go ahead.Speaker1Thank you all for participating in today's call. Earlier today, iRhythm released financial results for the second ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________________________ Form 10-Q _______________________________________________________________________ (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37918 ____________ ...

iRhythm Technologies Second Quarter 2025 Results July 31, 2025 Cautionary statement re forward-looking statements, non-GAAP measures and other matters Certain data in this presentation was obtained from various external sources, and neither "iRhythm Technologies, Inc. ("iRhythm" or the "Company") nor its affiliates, advisers or representatives has verified such data with independent sources. Accordingly, neither the Company nor any of its affiliates, advisers or representatives makes any representations as ...

Partnership aims to utilize predictive AI to help identify arrhythmias earlier in patient populations with an elevated risk for arrhythmias to enable timely care for millions who remain undiagnosedCommercial offering from this collaboration designed to support scalable population health and value-based care strategies SAN FRANCISCO, July 31, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a digital health leader focused on creating trusted solutions that detect, predict, and prevent disea ...

Exhibit 99.1 iRhythm Technologies Announces Second Quarter 2025 Financial Results SAN FRANCISCO, July 31, 2025 - iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended June 30, 2025. Second Quarter 2025 Financial Highlights Recent Operational Highlights "The second quarter of 2025 was another record quarter for iRhythm, with growth of more tha ...

iRhythm Technologies (IRTC) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on July 31, might help the stock move higher if these key numbers are better than ex ...

文章核心观点 iRhythm Technologies宣布将在2025年7月31日收盘后发布2025年第二季度财务结果并举行电话会议 [1] 公司信息 - 公司是专注于创建检测、预防和预测疾病可靠解决方案的领先数字医疗公司 [1][3] - 结合可穿戴生物传感器、基于云的数据和专有算法将数百万心跳数据转化为临床可操作信息 [3] - 愿景是为所有人提供更好的数据、见解和健康 [3] 财务信息 - 公司将在2025年7月31日收盘后发布2025年第二季度财务结果 [1] 会议信息 - 公司管理团队将在2025年7月31日下午1:30 PT/4:30 ET举行电话会议 [1] - 相关方可在公司投资者网站的“季度财报”板块观看会议直播和回放 [2] 联系方式 - 投资者联系人为Stephanie Zhadkevich 邮箱为investors@irhythmtech.com [4] - 媒体联系人为Kassandra Perry 邮箱为irhythm@highwirepr.com [4]

公司调查事件 - 律师事务所Kahn Swick & Foti正在对iRhythm Technologies公司展开调查 涉及公司高管及董事是否违反 fiduciary duties 或联邦法律 [1][3] - 调查背景源于2023年5月30日公司披露收到FDA警告信 涉及Zio AT系统在医疗器械报告要求和质量体系方面的不合规问题 [2] FDA监管问题 - FDA警告信指出Zio AT设备存在营销宣传与功能缺陷 可能对患者构成未披露风险 例如心律失常事件传输限制问题 [2] 法律诉讼进展 - 公司及部分高管因在Class Period期间未披露重大信息被提起证券集体诉讼 近期法院部分驳回公司驳回动议 案件将继续审理 [3] 律师事务所背景 - Kahn Swick & Foti为全美顶尖证券诉讼 boutique 律所 过去一年因和解金额位列SCAS评选的全美前10律所 在纽约 特拉华等多州设有办公室 [4][5]

公司董事会变动 - 公司宣布两位长期任职的董事会成员Mark Rubash和Ralph Snyderman博士退休，自2025年7月7日起生效 [1] - 同时任命Karen McGinnis和Kevin O'Boyle为新任董事会成员 [1] - Mark Rubash自2016年起担任董事，在公司首次公开募股前加入，拥有数十年在高增长科技公司的财务、会计和战略经验 [2] - Ralph Snyderman博士自2017年起担任董事，为公司早期应对数字技术挑战提供了临床专业知识和领导力 [2] 新任董事会成员背景 - Karen McGinnis拥有超过30年领导复杂国际公司的经验，涉及生物技术、消费电子、半导体和科技行业 [5] - 她曾担任Illumina首席会计官，领导全球会计和税务运营，并成功执行Mad Catz Interactive的全球重组计划 [5] - Kevin O'Boyle拥有20年高管领导经验，曾担任NuVasive执行副总裁兼首席财务官，帮助公司市值从1亿美元增长至20亿美元 [9] - 他在NuVasive期间连续23个季度达到或超过华尔街预期，年均复合增长率超过45% [9] 公司业务与愿景 - 公司是领先的数字医疗保健公司，专注于创建检测、预测和预防疾病的解决方案 [12] - 通过可穿戴生物传感器、云端数据分析和专有算法，将数百万次心跳数据转化为临床可操作信息 [12] - 公司愿景是通过对患者护理的持续关注，为所有人提供更好的数据、见解和健康 [12]

公司诉讼事件 - 股东代表在2022年1月11日至2023年5月30日期间购买或收购iRhythm Technologies Inc普通股的所有个人和实体提起集体诉讼 [1] - 公司被指控在集体诉讼期间向投资者虚假陈述Zio AT监护仪是针对高风险患者的实时监护设备 而公司传统产品Zio XT是为非危重患者设计的心电监护仪 不具备实时报告功能 [2] - 公司宣传Zio AT作为创新产品在实时监护市场的增长潜力 导致股价在诉讼期间被人为抬高 真相披露后股价下跌 [2] 诉讼进展 - 2025年6月3日法官Jacqueline S Corley部分批准部分驳回被告驳回起诉的动议 为针对iRhythm及其CEO的诉讼扫清道路 [3] 公司背景 - iRhythm Technologies是一家数字医疗公司 专注于开发和生产用于诊断心律失常的心脏监护设备 [1]